IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma

Blood

Volumn 92, Issue 6, 1998, Pages 1941-1949

  Bowman, Laura ^b   Grossmann, Michael ^b   Rill, Donna ^b   Brown, Michael ^b   Zhong, Wan Yun ^b   Alexander, Barbara ^b   Leimig, Thasia ^b   Coustan Smith, Elaine ^b   Campana, Dario ^b   Jenkins, Jesse ^b   Woods, Diane ^b   Kitchingman, Geoffrey ^b   Vanin, Elio ^b   Brenner, Malcolm ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; GENE THERAPY; GENETIC TRANSDUCTION; HELPER CELL; HUMAN; INFANT; NEUROBLASTOMA; PRIORITY JOURNAL;

EID: 17944389450     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.6.1941.418k03_1941_1949     Document Type: Article

References (48)

1. Fearon ER, Pardoll DM, Itaya T. Golumbek P. Levitsky HI, Simons JW, Karasuyama K, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397, 1990
2. Blankenstein T, Qin ZH, Uberla K, Muller W, Rosen H, Volk HD, Diamantstein T: Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 173:1047, 1991
3. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA: Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 146:3227, 1991
4. Russell SJ, Eccles SA, Flemming CL, Johnson CA, Collins MK: Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of TL-2 cDNA. Int J Cancer 47:244, 1991
5. Connor JP, Gansbacher B, Cronin K, Heston W, Fair W, Gilboa E: A new approach to the immunotherapy of bladder cancer using IL-2 gene transfer into MBT-2 cells. Proc Annu Meet Am Assoc Cancer Res 32:A1475 1991 (abstr)
6. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasvyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713, 1991
7. Tepper RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5:153, 1994
8. Anonymous Attachment IV Recombinant DN A Advisory Committee (RAC) Data Management Report - December 1994. Hum Gene Ther 6:1111, 1995
9. Nabel G, Gordon D, Bishop DK, Nickioff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chane AE: Immune response in human melanoma after transfer of allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 93:15388, 1996
10. Simons JW, Jaffe EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen AK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AHJ, Piantaodosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex-vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537, 1997
11. Hayes FA, Smith EI: Neuroblastoma, in Pizzo PA, Poplack DG (eds): Pediatric Oncology. Philadelphia. PA, Lippincott, 1989, p 607
12. D'Angio GJ, Evans AE, Koop CE: Special pattern of neuroblastoma with a favorable prognosis. Lancet 1:1046, 1991
13. Evans AE, Baum E, Chard R: Do infants with IVs neuroblastoma need treatment? Arch Dis Child 56:271, 1981
14. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM: Clinical relevance of tumor ploidy and n-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 9:581, 1991
15. Pritchard J, McElwain TJ, Graham-Pole J: High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45:86, 1982
16. Graham-Pole J, Casper J, Elfenbein G, Gee A, Gross A, Janssen W, Koch P, Marcus R, Pick T, Shuster J, Spruce W, Thomas P, Yeager A: High-dose chemotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 9:152, 1991
17. Anderson JR, Coccia PF: Is more better? Dose intensity in neuroblastoma. J Clin Oncol 9:902, 1991
18. Shuster JJ, Cantor AB, Me Williams N, Graham-Pole J Castleberry RP, Marcus R, Pick T, Smith EI, Hayes FA: The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 9:1045, 1991
19. Pinkerton CR: Where next with therapy in advanced neuroblastoma? Br J Cancer 61:351, 1990
20. Nsar S, McKolanis J, Pais R, Findley H, Hnath R, Waldrep K, Ragab AH: A phase T study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. Cancer 64:783, 1989
21. Negrier S, Michon J, Floret D, Bouffet E, Gentet JC, Philip I, Cochat P, Stamm D, Costil J, Gaspard M, Andrev G, Palmer P, Franks CR, Zucker JM, Bernard JL, Fridman WH, Favrot M, Philip T: Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 9:1363, 1991
22. Cheung NK: Immunotherapy. Neuroblastoma as a model. Pediatr Clin North Am 38:425, 1991
23. D2 oligosaccharide: Target for cytotoxic T lymphocytes. J Exp Med 182:67, 1995
24. Henderson RA, Finn OJ: Human tumor antigens are ready to fly. Adv Immunol 62:217, 1996
25. Fisch P, Malkovsky M, Kovats S, Sturm E, Brackman E, Klein BS, Voss SD, Morrissey LW, Demars R, Welch WJ: Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 250:1269, 1990
26. Sturm E, Braakman E, Fisch P, Vreugdenhil RJ, Sondel P, Bolhuis RL: Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J Immunol 145:3202, 1990
27. Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK: Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer 67:933, 1993
28. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB: Human neuroblastoma cell lines are susceptible to lysis by natural killer but not cytotoxic T lymphocytes. J Immunol 135:242, 1985
29. Reynolds JV, Shou J, Choi H, Sigal R, Ziegler MM, Daly JM: The influence of natural killer cells in neuroblastoma. Arch Surg 124:235, 1989
30. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234, 1990
31. Cheung NK, Burch L, Kushner BH, Munn DH: Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma (NB) patients (PTS) refractory to chemotherapy: a phase II trial. Proc Annu Meet Am Assoc Cancer Res 31:A1705 1990 (abstr)
32. Cheung NK, Medof ME, Munn D: Immunotherapy with GD2 specific monoclonal antibodies. Prog Clin Biol Res 271:619, 1988
33. Cheung NK, Yeh SD, Gulti S, Burch L, Kushner BH, Larson S: 131I-3F8 targeted radiotherapy of neuroblastoma (NB): a phase I clinical trial. Proc Annu Meet Am Assoc Cancer Res 31 : A1686 1990 (abstr)
34. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogen CW: Complement killing of human neuroblastoma cells: A cytotoxic monoclonal antibody and its F(ab)'-2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol 27:957, 1990
35. Munn DH, Cordon-Cardo C, Yeh SD, Kushner BH, Cheung NK: Therapy of neuroblastoma with GD2 specific monoclonal antibody 3F8, in Oettgen HF (ed): Gangliosides and Cancer. New York, NY, VCH, 1989, pp 259
36. Yu AL, Gillies SD, Reisfeld RA: Phase I clinical trial of Ch 14.18 in patients with refractory neuroblastoma. Proc Am Soc Clin Oncol 10:1118, 1991
37. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR: Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of pre-established retroperitoneal tumors. J Immunother 15:81, 1994
38. Brenner MK, Furman WL, Santana VM, Bowman L, Meyer W: Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. Hum Gene Ther 3:665, 1992
39. Zsengeller ZK, Wert SE, Hull WM, Hu X, Yei S: Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 6:459, 1994
40. Leimig T, Brenner M, Ramsey J, Vanin E, Blaese M, Dilloo D: High-efficiency transduction of freshly isolated human tumor cells using adenoviral IL-2 vectors. Hum Gene Ther 7:1233, 1995
41. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551, 1996
42. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407, 1994
43. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7:362, 1994
44. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernndez C, Gottlieb DJ, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK: Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 77:237, 1991
45. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307, 1993
46. Elliot JF, Lin Y, Mizel SB: Induction of Interleukin-2 messenger RNA inhibited by Cyclosporin A. Science 226:1439, 1984
47. Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immunotherapy of cancer using Interleukin-2. Ann Intern Med 108:853, 1988
48. Thompson RC, Pardoll DM, Jaffee EM: Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother 19:405 1996